Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FAGOX
- Development stage
- Preclinical
- Lead developer
- HEDROS Biotechnology
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
01
Overview
FAGOX is a bacteriophage-based product developed by HEDROS for the prevention and treatment of Acute Hepatopancreatic Necrosis Disease (AHPND) and other Vibrio infections in shrimp aquaculture. The product utilizes phage therapy, employing specific bacteriophages that target and lyse pathogenic Vibrio bacteria, particularly Vibrio parahaemolyticus strains that carry the pirABvp genes responsible for AHPND. By utilizing a sophisticated recognition process, FAGOX eliminates harmful bacterial strains with high specificity without disrupting beneficial microorganisms within the aquaculture ecosystem. It is intended as an eco-friendly and sustainable alternative to antibiotics for controlling mass mortality in farmed Pacific white shrimp (Litopenaeus vannamei).
- Brand names
- FAGOX
Beyond the preview
Go deeper on FAGOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FAGOX.